Floatz logo

Imu-201 (Pd1-Vaxx)

Squamous Non-small-cell Lung Cancer

Imugene LimitedPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the Squamous Non-small-cell Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
Gefetinib
Seoul Veterans Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Imu-201 (Pd1-Vaxx) is also rated in:

colorectal cancerDormant
CC
Indicative ·
46 / 100
View asset →
lung large cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
lung adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →